Pharma companies invest billions in psychedelic drug research despite regulatory hurdles
Major pharmaceutical firms are investing heavily in psychedelic medicines to treat depression and mood disorders after recent regulatory setbacks.
FDA rejection sparks renewed interest
The US Food and Drug Administration previously rejected an application for MDMA to treat post-traumatic stress disorder. This decision initially appeared to stall the entire field of psychedelic medicine development. Researchers remain confident that these treatments will advance despite the earlier refusal.
Eli Lilly makes major acquisition
In July, Eli Lilly announced plans to acquire AtaiBeckley for up to US$3.8 billion. The deal involves a New York City firm developing BPL-003 for treatment-resistant depression. This transaction highlights the growing financial commitment from large drug companies to this sector.
Investors see bright future
New clinical trial data suggests the industry is moving forward with renewed momentum. Billion-dollar investments indicate that confidence in these medicines has returned after a difficult period. Experts believe the regulatory pushback stimulated important conversations rather than ending the research.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.